JPY 214.0
(0.47%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 1 Million USD | 0.0% |
2022 | - USD | -100.0% |
2021 | 4.03 Million USD | 0.0% |
2020 | - USD | 0.0% |
2019 | - USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | - USD | 0.0% |
2024 Q2 | - USD | 0.0% |
2023 Q4 | - USD | -100.0% |
2023 FY | 1 Million USD | 0.0% |
2023 Q3 | 1 Million USD | 0.0% |
2023 Q2 | - USD | 0.0% |
2023 Q1 | - USD | 0.0% |
2022 FY | - USD | -100.0% |
2022 Q4 | - USD | 0.0% |
2021 FY | 4.03 Million USD | 0.0% |
2020 FY | - USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
KOHJIN BIO CO LTD | 1.88 Billion JPY | 99.947% |
PRISM BioLab Co.,LTD | 80.3 Million JPY | 98.755% |
GNI Group Ltd. | 22.43 Billion JPY | 99.996% |
Linical Co., Ltd. | 3.77 Billion JPY | 99.974% |
Trans Genic Inc. | 2.24 Billion JPY | 99.956% |
MEDINET Co., Ltd. | 98.25 Million JPY | 98.982% |
Soiken Holdings Inc. | 2.48 Billion JPY | 99.96% |
Cytori Cell Research Institute, Inc. | 1.29 Billion JPY | 99.923% |
AnGes, Inc. | -3.06 Billion JPY | 100.033% |
OncoTherapy Science, Inc. | -177.71 Million JPY | 100.563% |
Nxera Pharma Co., Ltd. | 9.66 Billion JPY | 99.99% |
Immuno-Biological Laboratories Co., Ltd. | 517.29 Million JPY | 99.807% |
NanoCarrier Co., Ltd. | 110.95 Million JPY | 99.099% |
Carna Biosciences, Inc. | 1.45 Billion JPY | 99.931% |
CanBas Co., Ltd. | -984 Million JPY | 100.102% |
D. Western Therapeutics Institute, Inc. | 391.69 Million JPY | 99.745% |
RaQualia Pharma Inc. | 1.65 Billion JPY | 99.94% |
Chiome Bioscience Inc. | 398.59 Million JPY | 99.749% |
Kidswell Bio Corporation | 1.03 Billion JPY | 99.904% |
PeptiDream Inc. | 17.21 Billion JPY | 99.994% |
Oncolys BioPharma Inc. | 30.6 Million JPY | 96.733% |
Ribomic Inc. | -10.5 Million JPY | 109.522% |
SanBio Company Limited | -14.5 Million JPY | 106.895% |
Healios K.K. | 108 Million JPY | 99.074% |
BrightPath Biotherapeutics Co., Ltd. | -341 Thousand JPY | 393.255% |
Kubota Pharmaceutical Holdings Co., Ltd. | -59.04 Million JPY | 101.694% |
Delta-Fly Pharma, Inc. | -1.51 Million JPY | 166.138% |
StemRIM | -44.34 Million JPY | 102.255% |
CellSource Co., Ltd. | 3.18 Billion JPY | 99.969% |
FunPep Company Limited | -680.28 Million JPY | 100.147% |
Kringle Pharma, Inc. | 69.25 Million JPY | 98.556% |
Stella Pharma Corporation | 217.29 Million JPY | 99.54% |
TMS Co., Ltd. | -6.95 Million JPY | 114.388% |
Noile-Immune Biotech Inc. | 314.56 Million JPY | 99.682% |
Cuorips Inc. | 9.63 Million JPY | 89.617% |
K Pharma,Inc. | 910 Million JPY | 99.89% |
Takara Bio Inc. | 25.45 Billion JPY | 99.996% |
ReproCELL Incorporated | 1.1 Billion JPY | 99.909% |
PhoenixBio Co., Ltd. | 1.19 Billion JPY | 99.916% |
StemCell Institute Inc. | 1.57 Billion JPY | 99.937% |
Japan Tissue Engineering Co., Ltd. | 1.66 Billion JPY | 99.94% |
CellSeed Inc. | 107.15 Million JPY | 99.067% |